Slide 1: Corporate Presentation
Corporate Presentation As of April 1, 2026
Slide 2: Important Information
Important Information The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer session and any document or material distributed at or in co
Slide 3: PureTech Overview
PureTech Overview We are dedicated to giving life to science and transforming innovation into value Pioneer of the hub-and-spoke R&D model What is it: The “hub” drives new innovations and early program A Boston-based, LSE-listed, advancements, which are spun out into Founded Entities hub-and-spoke (
Slide 4: Our Innovative Approach to Development
Our Innovative Approach to Development Unlocking value from therapeutics with clinically-validated pharmacology CRITERIA APPROACH Development anchored to key validation/value inflection points Mechanism validated in prior human studies Capital deployed selectively as conviction increases Clear disea
Slide 5: Our Proven and Seasoned Team
Our Proven and Seasoned Team Robert Lyne Eric Elenko, PhD Michael Inbar, CPA, MBA Charles Sherwood, JD Chief Executive Officer Co-founder & President Chief Accounting Officer General Counsel Former CEO at Arix Bioscience (acq. by RTW Co-founder and acting C-level executive of Former CFO at Acronis I
Slide 6: Our World Class Board of Directors
Our World Class Board of Directors Our board has contributed to regulatory approvals of over 15 drugs and has led multi-billion-dollar strategic transactions Sharon Barber-Lui Robert Langer, ScD John LaMattina, PhD Interim Board Chair Board Board CFO & Senior VP of Teva Pharma, Former CFO of Merck &
Slide 7: PureTech's Core Components of Value Creation
PureTech’s Core Components of Value Creation Phase 3 ready program with potential to become new standard of care in IPF Significant potential upside within >$10B market1 100% equity holding2; intend to secure external capital Differentiated clinical-stage program addressing ~$6B3 and growing
Slide 8: Celea Therapeutics (PureTech's Economic Interest: 100%)
Celea Therapeutics (PureTech’s Economic Interest: 100%) Advancing deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) IPF is a progressive and fatal disease with a significantly unaddressed patient population >232,000 ~2-5 years IPF patients in the U.S. & EU51 Involves scarring o
Slide 9: Celea Therapeutics (Cont'd)
Celea Therapeutics (Cont’d) Deupirfenidone has the potential to become the next standard-of-care for IPF Deupirfenidone is a novel, oral small molecule Open-label extension trial ongoing Next generation antifibrotic & deuterated form Initial data support the durability of treatment of pirfenidone, o
Slide 10: Deupirfenidone Has Demonstrated Potential for Best-in-class Efficacy
Deupirfenidone Has Demonstrated Potential for Best-in-class Efficacy FVC Relative Benefit Over Placebo Indirect comparison. Not based on head-to-head data Deupirfenidone 825 mg (Ph 2b ELEVATE IPF 26 weeks) no background 81% Deupirfenidone 825 mg (Ph 2b ELEVATE IPF OLE 52 weeks*) no background 84% Pi
Slide 11: Celea Therapeutics (Cont'd)
Celea Therapeutics (Cont’d) Strong data package as a Why Deupirfenidone? monotherapy; first therapy to show potential lung function normalization in IPF Broad potential to be the new SOC for IPF patients Best-in-class efficacy: first and only IPF treatment to show improved Estimated total ad
Slide 12: Gallop Oncology (PureTech's Economic Interest: 100%)
Gallop Oncology (PureTech’s Economic Interest: 100%) Advancing LYT-200, galectin-9 targeting mAb, for the treatment of hematological malignancies Challenge • Current therapies predominantly only address Gear 1 or Gear 2 LYT-200 Gear 1 Gear 2 Solution Kills cancer cells Kills cancer cells directly th
Slide 13: Data Cut from Phase 1b Trial in AML/MDS Presented at ASH
Data Cut from Phase 1b Trial in AML/MDS1 Presented at ASH LYT-200 Phase 1b Early Data2 Proposed Phase 2 Dose 12 mg/kg in Combination with Ven/Aza in Evaluable Patients3 (N=32) Median Progression-free 4.5 months Survival Survival Median Overall Survival 13.2 months 38% Combined Complete Response 43%
Slide 14: Seaport Therapeutics (PureTech Economic Interest: 35.1%)
Seaport Therapeutics (PureTech Economic Interest: 35.1%1) Advancing a clinical-stage pipeline of novel neuropsychiatric medicines UNLOCKING BACKED BY TOP TIER PROVEN TEAM NEW MEDICINES GLYPH PLATFORM INVESTORS Supported by leading investors Advancing novel Uniquely designed to Track record of succes
Slide 15: Seaport Therapeutics (Cont'd)
Seaport Therapeutics (Cont’d) Pipeline of potentially first & best-in-class new medicines for anxiety & depression SEAPORT PROGRAMS1 GLYPH BENEFIT DISCOVERY PRECLINICAL PHASE 1 PHASE 2 GlyphAllo (SPT-300) Overcome lack of Glyph Allopregnanolone oral bioavailability Major depressive disorder (MDD) Ne
Slide 16: Case Study of Clinical & Financial Success: Karuna Therapeutics
Case Study of Clinical & Financial Success: Karuna Therapeutics Acquired by Bristol Myers Squibb for $14 billion on March 18, 2024 CLINICAL SUCCESS FINANCIAL SUCCESS ▶ (formerly Karuna’s KarXT) now FDA approved for the treatment of schizophrenia in adults ▶ 1st new mechanism for treating schizophren
Slide 17: Cobenfy Economics to PureTech Based on Analyst Forecasts
Cobenfy Economics to PureTech Based on Analyst Forecasts Potential ~$300 million in economic value to PureTech between 2025-20331 based on analyst consensus for Cobenfy sales projections2 ($ in millions) 2025 2026 2027 2028 2029 2030 2031 2032 2033 $137- $274- $501- $626- $720- $792- $832- $832- $2,
Slide 18: 2026 Key Priorities & Catalysts
2026 Key Priorities & Catalysts OPERATIONAL FOCUS Secure external funding for Celea Therapeutics H1 2026 Secure external funding for Gallop Oncology 2026 Streamline spend Ongoing CLINICAL MILESTONES Initiation of Phase 3 SURPASS-IPF trial in IPF H1 2026 Final results from Phase 1b trial in
Slide 19: Analyst Coverage
Nasdaq Global Market & LSE Main Market / FTSE-indexed: PRTC Headquartered in Seaport, Boston 243,418,190 outstanding shares $319.6M PureTech Level Cash, as of March 31, 2026 Cash Equivalents & Short-Term Investments as of June 30, 20251 ANALYST COVERAGE Peel Hunt LLP Miles Dixon Substantial sharehol
Slide 20: Financial Highlights
Financial Highlights June 30, 2025 June 30, 2024 $ millions $ millions Cash Flow and Liquidity Cash and Cash Equivalents 260.6 308.5 Short-term investments 59.3 191.9 Consolidated Cash, cash equivalents and short-term investments 319.9 500.4 Less: Cash and Cash Equivalents held at non-wholly-owned s
Slide 21: Non-IFRS Measures
Non-IFRS Measures Reported Performance Reported performance considers all factors that have affected the results of our business, as reflected in our condensed consolidated financial statements. Core Performance Core performance measures are alternative performance measures which are adjusted and no